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Abstract: In mammals iron deficiency (ID) may contribute to hyperglycemia and 
dyslipidemia.  Similar changes in glucose and lipid metabolism are observed in response 
to abnormalities in circadian rhythm. The nuclear hormone receptors (NHR) REV-ERBα 
and REV-ERBβ are heme-regulated transcription factors that are critical to the 
maintenance of circadian rhythm [1], [2]. Cellular oscillations in circadian rhythm are 
controlled through a network of negative feedback and feed-forward loops that regulate 
the transcription of clock-related and metabolic genes. In the presence of heme, REV-
ERBs repress transcription of Bmal1, G6pase, and Pepck in the liver and reduced heme 
levels leads to de-repression of these genes [3]. In skeletal muscle, targets of REV-ERBs 
such as Bmal1 regulate the transcription of MyoD, Pgc-1α and Pgc-1β, proteins that are 
involved in cellular differentiation and metabolic function [4]. Bmal1 expression is also 
controlled by another NHR, RORα which activates the transcription of Bmal1. 
Expression profiling in skeletal muscle of clock mutant mice showed that skeletal muscle 
specific gene expression MyoD and Pdk4, which are important for cell proliferation and 
glucose metabolism, were dyregulated. The aim of the study was to investigate the effect 
of iron status on the regulation of circadian rhythm and cellular metabolism in C2C12 
myoblast and myotubes. C2C12 myoblasts and myotubes were treated with the iron 
chelator desferroxamine (DFO) or iron in the form of ferric ammonium citrate (FAC) or 
hemin. RNA was extracted for gene expression analyses. Rhythmicity in circadian genes 
was altered by iron chelation and iron loading in C2C12 myoblasts and myotubes. Iron 
chelation decreased iron availability for heme biosynthesis resulting in a de-repression of 
REV-ERBα activity and transactivation of Bmal1 gene expression in both myotubes and 
myoblasts. These findings are consistent with studies in ID animals. Low cellular iron 
status may potentially dysregulate CLOCK:BMAL modulations of its target gene (MyoD 
, Pgc-1α and Pgc-1β). Bmal1 and Tfrc response to a decrease in iron status in both 
C2C12 myoblasts and myotubes and are similar to observations in the skeletal muscle of 
ID animals. Additional studies may be required to understand the mechanisms that 
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Disruption of circadian rhythm by dietary changes, shift work, long distance air travel, 
and artificial lighting at night is increasingly prevalence in today’s society [5]–[7]. Multiple 
studies have suggests that chronic disruption of circadian rhythmicity may lead to pathological 
consequences such as obesity, metabolic diseases, inflammatory disorders and cancer [5]–[7]. 
Skeletal muscle, like other tissues, expressed circadian rhythmicity. When circadian rhythms are 
disrupted in skeletal muscles, alteration in muscle composition and function are correlated with 
disease development such as diabetes cardiovascular disease and cancer [8]. These disorders are 
associated with decreased muscle mass, and impaired muscle metabolism [8]. Loss of skeletal 
mass is also associated with decreased insulin insensitivity in skeletal muscle which is involved in 
development of type 2 diabetes [8]–[10]. Thus, circadian disruption is a critical detrimental factor 
of skeletal muscle health [8], [11], [12]. 
Circadian rhythms (in Latin ‘circa diem’; meaning ‘about a day’) were first observed in 
plants and over the past centuries, discoveries were extended to almost all life forms [13]–[15]. 
The circadian clocks are critical in coordinating the physiology and behavior of mammalian at a 
24 hour light-dark cycle, allowing temporal regulation of body metabolism and homeostasis [16], 
[17]. Other than light, entrainment of circadian clock to the environment and food availability is 
essential [5], [13], [14], [16], [18]–[20]. In mammals, suprachiasmatic nucleus (SCN) is 
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programmed to control circadian time based on light-dark signal, as well as signals from feeding 
and sleeping [6], [4]. Even though the core circadian regulation is found in the SCN, peripheral 
tissues have cell autonomous circadian control [21], [22]. An iron-containing nutrient, heme, has 
demonstrated to affect regulation of circadian and metabolic pathways through activation of 
circadian repressor, REV-ERBα [2], [14], [23], [24]. Additionally, dietary iron has been recently 
shown to modulate circadian rhythm and heme biosynthesis in liver by repression of 
gluconeogenic gene expression Pepck and G6pase by REV-ERBα [3]. These observations 
suggest that nutritional signaling by heme is a critical factor in circadian regulation. Despite an 
understanding of interaction between circadian regulation and metabolism in response to dietary 
iron in the liver, the response of circadian clock to iron status in the skeletal muscle has yet to be 
clearly elucidated. 
REV-ERBα is a nuclear hormone receptor that regulates circadian rhythm, lipid 
metabolism and cellular differentiation [16]. Heme, an iron containing porphyrin ring, is ligand of 
REV-ERBα that repressed the circadian gene expression Bmal1which is involved in core clock 
metabolism [2], [16], [24]–[26]. Other than Bmal1 gene expression, REV-ERBα is important in 
regulating clock-controlled genes such as Pgc-1α for mitochondrial biogenesis and the muscle 
specific gene, MyoD [20], [4], [21], [22]. Disruption of circadian rhythm in Bmal1 knockout and 
Clock mutant mice has led to diet-induced obesity, hyperlipidemia, hepatic steatosis and 
hypoinsulinemic hyperglycemia, diabetes and age-related myopathy [12], [14], [27]–[29]. These 
findings demonstrate the disruption of downstream gene expression regulates by heme-mediated 
REV-ERBα potentially lead to metabolic disorders. Iron is an essential micronutrient involves in 
metabolic and cellular processes such as oxygen transport, energy transformation, DNA 
synthesis, cellular proliferation and heme biosynthesis [30].  
Iron deficiency is a pronounced problem in both developed and developing countries, 
affecting almost 30% of the world populations [31]. Despite advanced development of nutritional 
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sciences and improved standard of living, iron deficiency is estimated to impact nine million 
people and affecting mostly pregnant women and young adolescent in the United States [32], 
[33]. The disturbance of iron-dependent systemic and cellular homeostasis due to iron deficiency 
has been shown to enhance metabolic syndromes and diseases such as hyperglycemia, 
accumulation of lipid, weight gain, muscle fatigue and mitochondrial myopathy [12], [29], [33], 
[34]. Our preliminary studies on 21 days iron deficient rats showed that they exhibit a disruption 
in lipogenesis, glycolytic, iron metabolism as well as circadian gene expression. The effect of 
nutrition (iron) showed strong linked between alteration and dysfunction in metabolism and 
circadian gene expression[13]. Intriguingly, both iron deficiency and circadian disruption 
negatively affect skeletal muscle health. These studies reveal that there is a correlation between 
circadian and metabolic regulation that lead to these similar metabolic syndromes. 
REV-ERBα regulates PGC-1α pathway which is important for heme homeostasis in the 
liver [3], [25]. The transcription of the coactivator PGC-1α is a potent transcriptional activator of 
the rate-limiting enzyme Alas1 in heme biosynthesis [3], [25]. Moreover, PGC-1 α, regulator of 
energy metabolism and mitochondrial biogenesis, also coactivate the expression of Bmal1 and 
Rev-erbs [35]. Iron is necessary for heme biosynthesis and heme plays a role in oxygen transport, 
ATP synthesis and circadian rhythm. In iron deficiency, heme and ISC biogenesis are 
compromised and dysregulate cellular and mitochondrial function [36], [37]. These studies 
showed that there is a possible regulation of iron status on circadian and metabolic pathway 
through heme biosynthesis. Despite an understanding of interaction between iron status and 
circadian-regulated heme biosynthesis in the liver, the iron-dependent mechanism that regulates 
circadian-regulated heme biosynthesis in skeletal muscle is not clearly elucidated.  
Cellular iron is the key regulator of mitochondrial biogenesis [30]. Iron depletion in 
mouse muscle cells resulted in decrease in mitochondrial protein level and oxidative capacity 
[38]–[43]. Surprisingly, iron deficiency in the liver showed no significant change in mitochondria 
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activity [38]–[43]. The degree that iron status coordinates circadian metabolism and mitochondria 
function in the skeletal muscle has not been substantially elucidated. 
MyoD is a known clock-controlled gene specific to skeletal muscle and function as 
regulator of myogenesis [12], [44], [45]. Iron deficiency stunt growth in adolescent and MyoD is 
one of the important regulator of muscle growth and differentiation that is controlled in a 
circadian manner by REV-ERBα [12], [45]–[47]. Co-activators PGC-1α and PPAR family, as 
well as HIF1α are important for up-regulation Pdk4 which is involved in glucose metabolism 
[48], [49]. Circadian protein REV-ERBα binds upstream of insig2 transcript which activates 
nSREBP-1c for fatty acid and cholesterol metabolism in the liver [50]. Pdk4 and Srebp1c gene 
expression are altered in skeletal muscle of iron deficient rats and these genes have been shown to 
be regulated in a circadian manner and are involves in glucose metabolism and fatty acid and 
lipid production in skeletal muscles [50]–[55]. Pdk4 alteration in gene expression may be due to 
the increased activity of HIF1α by hypoxia mimetic desferroxamine, which is commonly used as 
an iron chelator in cell culture experiments [56] . Despite various studies on muscle circadian 
regulation, the degree to which alteration in iron status could potentially regulate these critical 
circadian components remains unknown. 
These findings lead to the proposed examination on impact of iron depletion and iron 
loading on circadian and metabolic gene expression in C2C12 synchronized myoblast and 
myotubes which model the physiological state of proliferating and differentiating muscle cells. 
The relationship of iron status and regulation of Bmal1 and Rev-erbα gene expression may reveal 
the impact of iron status on circadian rhythm and its metabolic gene expression specific to 
skeletal muscle cells.  
Our objectives were to further examine and characterize the effect of iron status on the 
alteration in circadian and metabolic gene expression in synchronized C2C12 myoblast in vitro. 
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Our central hypothesis was that iron chelation and iron loading would alter circadian and 
metabolic gene expression involved in mitochondrial function, myogenesis, macronutrient 
metabolism in C2C12 myoblast. Furthermore, we hypothesized that chelation and loading of iron 
would alter mitochondrial function and oxidative capacity. Thus, the results presented herein will 
provide insight to potential relationship between cellular iron status and circadian rhythm as well 









Molecular Clock in Mammals, transcriptional control and regulation 
  Circadian rhythms (in Latin ‘circa diem’; meaning ‘about a day’) were first observed in 
plants and over the past centuries, discoveries were extended to almost all life forms such as 
drosophila, bacteria, yeast and mammalians [13]–[15]. The circadian clocks are critical in 
coordinating the physiology and behavior of mammalian at a 24 hour light-dark cycle, allowing 
temporal regulation of body metabolism and homeostasis [13], [14], [16]–[18]. The complexity of 
circadian rhythms within a cells involves the intracellular regulation of many other cellular 
processes such as transcription regulation, cell cycle and metabolism [57], [58]. Circadian rhythm 
is regulated by two clocks: the master clock in the brain and peripheral clocks in other tissues 
[59]. The master clock in the suprachiasmatic nucleus (SCN) of hypothalamus received the light 
input from the retina, resulting in the transmission of electrical signal through the nerves in 
hypothalamus which activate neuronal and hormonal pathway that synchronizes circadian timing 
in brain and other tissues such as liver, adipose tissues, pancreas, and skeletal muscles [14], [16], 
[59].  
Over the past decades, mammalian clocks in the peripheral tissues were thought to occur 
through neuronal-hormonal signaling from SCN [60]–[64]. However, recent studies showed that 
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peripherals tissue are capable of adapting locally to the metabolic status of the tissues [14], [16], 
[60], [65]. The peripheral clocks can be entrained independent of signals from SCN through the 
regulation from external temperature and feeding cues [65]. The rhythmic changes observed in 
metabolic and cell signaling pathways occurred when the mammals adapt to environment changes 
by altering the body circadian rhythm through heat shock signaling and other hormonal and 
neuronal pathways [14]. Other than environmental temperature, feeding cues have been shown to 
entrain metabolic and hormonal pathways and can behave as the dominant factor, instead of SCN, 
for setting circadian clock in peripheral tissues [60]. The changes in circadian rhythm by 
environmental and feeding cues allow the body to adapt to the environmental changes and reset 
oscillating phase (i.e. length and amplitude) [14]. 
At the molecular level, the mammalian circadian clock is a highly conserved system 
involving the interaction of mRNA and protein in the circadian clock transcription-translation 
feedback loop (TTFL) (Figure 1) [4]. Within the TTFL, there are primary and secondary 
regulatory feedback loops. In the primary loop, the auto-regulatory feedback loop is involved in 
the core molecular CLOCK (Circadian Locomotor Output Cycles Kaput) and BMAL1 (Brain 
Muscle ARNT-like 1), which play important roles as a PAS-bHLH transcriptional activator in 
driving the time keeping mechanism in mammals [4], [60], [61], [64], [66]–[68]. The activation 
of other clock genes is mediated by the activation of histone acetyl transferase (HAT) of CLOCK 
protein [69], [70]. Dimerization and binding of CLOCK and BMAL heterodimers onto conserved 
E-box (CACGTG) sequences in the promoter region of its target genes drives the circadian gene 
expression Period (Per1 and Per2) and Cryptochrome (Cry1, Cry2, Cry3) as well as the nuclear 
hormone receptor Rorα (RAR-related orphan receptor alpha), and Rev-erbα (Nr1d1; nuclear 
receptor subfamily 1 group D member 1) [4], [71].  
The secondary regulatory loop involves the nuclear hormone receptors REV-ERBα and 
RORα which are negative and positive transcriptional regulator of their target genes Bmal1, 
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respectively. REV-ERBα recruits NcoR (nuclear receptor co-repressor) and histone deacetylase 
(HDAC3) upstream of Bmal1 and prevents its transcription. Decreased in BMAL1 indicates 
binding of REV-ERBα onto RORE (AAAGTAGGTTA) sequences in the promoter region of 
Bmal1 encoded gene, resulting in inactivation of Bmal1 transcription [72], [73]. Decrease in 
BMAL1 for dimerization with CLOCK protein result in decrease in the transcription of 
downstream target genes, Per, Cry, Rev-erba, and Rora. Binding of activated RORα onto E-box 
upstream of Bmal1 promotes Bmal1 transcriptional activation. As BMAL1 protein is made, 
hyperphosphorylation occurred in the PER:CRY and CLOCK:BMAL1 complexes which signal 
them for degradation [4]. CLOCK protein is not rhythmic, however, it is important circadian 
protein that has HAT activity and binding of BMAL1 to CLOCK enhance the activity of HAT for 
circadian regulation [74]. Despite the known mechanism of CLOCK protein in circadian 
regulation and the circadian disruption of Clock-/-, the regulation of Clock gene expression is not 
well understood at present. 
This transcription-translation feedback loop is important in maintaining circadian 
regulation in the cell at different time of the day [4]. The well coordinate transcription and 
translation of this feedback loop maintain cell at different stages of its life, such as growth and 




Figure 1: Molecular circadian clock in mammals (revised from Golombek D.A. et al.) [75]. This 
figure illustrates the primary and secondary feedback loop in the transcriptional and translational 
regulation in molecular circadian system. In the primary regulatory loop, the Per and Cry gene 
expression gets activated by CLOCK:BMAL1 heterodimer by binding to E-box sequence 
(CACGTG) upstream of the their target genes. As PER and CRY protein are made, they form a 
heterodimer and function by inhibiting their own transcription by repression of CLOCK:BMAL1 
activity. In the secondary regulatory feedback loop, the nuclear hormone receptor, REV-ERBα 
and RORα function to repress and activate, respectively, by competitive binding to RORE on 




REV-ERBα and RORα regulate circadian rhythm and metabolic function 
Mammalian rhythmic regulations such as development and reproduction are dependent 
on changes in hormones and metabolites (i.e. vitamins, lipids, and heme) which bind to nuclear 
hormone receptor ligand binding domain (LBD) [73], [76]. Nuclear hormone receptor behaves as 
a transcription co-regulator that activates or represses target gene expression by chromatin 
remodeling via histone modification [77].  The multiple loop of regulation between nuclear 
hormone receptors (REV-ERBα and RORα) and the core clock mechanism suggest that circadian 
regulation is a complex process [76].  
There are two types of nuclear hormone receptors: co-activators (RORα) and co-
repressors (REV-ERBα). The regulation of gene expression occurs when specific ligand is bound 
to nuclear hormone receptor protein resulting in activation through a conformation change in 
protein structure [77]. Oxysterols and heme are specific ligands that bind to RORα and REV-
ERBα, respectively. When oxysterol is bound to the coactivator RORα, the activity of HAT 
loosen the linkage of histones to DNA which in turn activates gene expression [77]. Moreover, 
PGC-1α acts as a co-activator of RORα [78], [79]. When heme is bound to corepressor REV-
ERBα, a protein conformational change occurs resulting in recruitment of NcoR and HDAC3 
which tightens the association of histones to DNA, thus preventing gene transcription [23], [77]. 
REV-ERBα and RORα are important nuclear hormone receptors that regulate core clock 
metabolism and gene expression. 
REV-ERBα and heme homeostasis 
Heme biosynthesis has been extensively examined in past decades, and the gene and 
structural form of the enzymes involved has been discovered [80]. Heme influences the 
metabolism and circadian rhythm by serving as a cofactor for REV-ERBα protein.  
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Heme binds to REV-ERB ligand binding domain and stabilized the REV-ERB proteins, 
resulting in the repression of target genes by the recruitment of NcoR co-repressor and HDAC3 
[23], [77]. Heme binding is specific to REV-ERB LBDs as no effect of heme on other nuclear 
receptor such as LXR was observed [81]. The affinity of heme for REV-ERB LBD (Kd = 3 μM) 
suggests that these receptors are ‘metabolite’ sensor such as FXR (bile acid), LXR (oxysterol),  
RORα (oxysterol) and PPAR (fatty acids) [77], [81]. Heme binding to REV-ERB ligand binding 
proteins is reversible and REV-ERBs function as heme sensor rather than modulator in redox 
condition or diatomic gases (i.e. NO) [23], [81]. A study had shown that histidine602 (H602) is 
crucial for the binding of heme on REV-ERBs and it is conserved in REV-ERBα [23]. Structural 
mutant REV-ERBα (H602F) had been shown to impair heme binding to LBDs [2], [23]. Hence, 
we know that heme is specific to the binding domain in REV-ERBα.  
Heme biosynthesis is control in a circadian manner [3], [25], [82]. Intracellular heme 
have been shown to oscillate in a circadian manner in NIH3T3 cells, however, their significance 
was unknown [82]. The rate-limiting enzyme, aminolevulenic acid (ALAS1), is induced during 
heme biosynthesis by nuclear receptor coactivator PGC-1α by binding to NRF1 and FOXO1 
which activates Alas1 gene expression [25]. Heme controls its own synthesis by feedback 
inhibition of Alas1 gene expression [3], [83]. Moreover, increase in intracellular heme induces its 
own degradation through heme-oxygenase (HMOX-1) whose gene expression is induced by free 
heme as well as oxidative stress [84].  Wu et al. has identified two RORE binding site within the 
first intron region Pgc-1α gene and they are conserved in mouse and human [25]. Moreover, the 
study showed that in HepG2 cells, REV-ERBα directly represses Pgc-1α transcription via binding 
of RORE and heme induces Alas1 and Pgc-1α gene expression in HepG2 cells [25].  
 These studies demonstrate that heme is a specific metabolite that binds to the LBD on 
nuclear hormone receptor REV-ERBα and rhythmic variation in intracellular heme modulates 
Alas1 and Pgc-1α gene expression, via binding of heme to REV-ERB, which is important for 
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homeostasis of heme biosynthesis. Moreover, heme-mediated REV-ERBs modulate repression of 
their target genes such as Bmal1 and Pgc-1α therefore, shaping the appropriate amplitude for its 
circadian rhythm and heme biosynthesis. These demonstrate the important of heme in circadian 
and heme biosynthesis regulation. 
Disruption of Circadian Rhythm 
Disruption of circadian rhythm by dietary changes, shift work, long distance air travel, 
and artificial lighting at night is increasingly prevalence in today’s society [5]–[7]. Multiple 
studies have suggested that chronic disruption of circadian rhythmicity may lead to pathological 
consequences such as obesity, metabolic diseases, inflammatory disorders and cancer [5]–[7]. 
Mice lacking REV-ERBα experienced disorganized circadian rhythm [14], [72], [85]. In 
C57BL/6 mice, loss of both Rev-erbs in the liver result in decrease in circadian gene expression 
and hepatic steatosis [85], [86]. Recently, Simcox et al. have demonstrated that dietary iron 
affects circadian glucose metabolism in the liver through regulation of heme biosynthesis [3]. 
Free heme was suggested to induce production of ROS and activates PGC-1α which in turn up-
regulates Alas1 gene expression and heme biosynthesis [3]. 
Skeletal muscle, like other tissues, expressed circadian rhythmicity. Circadian study in 
skeletal muscle is still in the early stages. When circadian rhythms are disrupted in skeletal 
muscles, alteration in muscle composition and function are correlated with disease development 
such as diabetes cardiovascular disease and cancer [8]. These disorders are associated with 
decrease muscle mass, reduced mitochondria volume and impaired muscle metabolism [8]. Loss 
of skeletal mass is also associated with decreased insulin insensitivity in skeletal muscle which is 
involved in development of type 2 diabetes [8]–[10]. Thus, circadian disruption is a critically 
detrimental factor to skeletal muscle health [8], [11], [12].The metabolic disorders observed in 
disrupted circadian rhythm are similar to those observed in iron deficient rat’s skeletal muscle 
(i.e. low muscle mass, reduced mitochondria volume and function) . Therefore, further 
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investigation is required to understand the relationship between iron status and circadian rhythm 
in skeletal muscle.  
Circadian Rhythm in Skeletal Muscles 
In the past decades, skeletal muscle circadian transcriptome, diurnal gene expression and 
bioinformatics analysis have been reported, therefore, assisted the understanding and future 
studies of circadian rhythm in skeletal muscles [87]–[90]. Approximately 7% of skeletal muscle 
transcriptome have been identified to express in circadian manner [4], [89], [91]. Within the 7% 
transcriptome, 18% are involved in the biosynthesis and metabolism and 17% are involved in the 
regulation of gene transcription [87], [91]. 
The bioinformatics analysis by McCarthy et al. showed that known core clock genes 
Bmal1, Per2 and Cry2 as well as metabolic genes, Pdk4, expressed circadian rhythmicity in 
skeletal muscle [89]. In Cry1-/- and Cry2-/- mice, complete loss of circadian gene oscillation is 
observed, therefore Cry1 and Cry2 are both essential in maintaining circadian rhythmicity in 
mammals [92]. The tissue-specific metabolic genes expressed in skeletal muscle such as MyoD 
(myogenic differentiation) has also been identified and regulate by REV-ERB and 
CLOCK:BMAL1 heterodimer [89]. SREBP-1c, a regulator of cholesterol and fatty acid 
metabolism, has been identify to be under circadian control of REV-ERBs through regulation of 




Figure 2: Regulation of metabolic genes (Insig2, Srebp1c, Fas, Hmgcr, Alas1, Pdk4, MyoD, Pgc-
1α and Pgc-1β) by circadian regulators and circadian mediated regulators such as REV-ERBα, 
CLOCK:BMAL1 and PGC-1α [48], [78], [87], [89], [96], [97]. Insig2: Insulin induced gene 2; 
Srebp1c: Sterol regulatory element binding transcription factor 1; Fas: Fatty acid synthase; 
Hmgcr: HMG-CoA reductase; Alas1: Aminolevulinic acid; Pdk4: Pyruvate dehydrogenase 
kinase, isozyme 4; MyoD: Myogenic differentiation; Pgc-1α and Pgc-1β: Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha and beta.  
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REV-ERB and myogenesis 
REV-ERBα has specific function in different tissues such as liver, adipose tissue, 
pancreas, brain and macrophages [98]. Rev-erbα is highly expressed in oxidative skeletal muscle 
and REV-ERBα protein modulates myogenesis by repression MyoD gene expression required for 
muscle cell differentiation [98]. 
The myogenic basic helix-loop-helix (myo-bHLH) MyoD is a known clock-controlled 
gene in skeletal muscle and function as muscle regulator of myogenesis [4], [12], [46], [47]. 
During myogenesis, cell cycle arrest occurs in the mononucleated proliferating myoblasts 
together with increased production of MYOD protein, resulting in fusion into myotubes [47]. 
Isolation of undifferentiated synchronized myoblast have shown that the ability for cell to 
differentiate is linked to MyoD expression level [47], [99]. A certain level of MyoD protein must 
be expressed before myoblast undergoes differentiation [47]. Other than growth factors, upstream 
regulation of MyoD is also controlled by core clock genes CLOCK and BMAL and the nuclear 
hormone receptor REV-ERBα [89].  
REV-ERB and energy metabolism 
PGC-1α is a transcription coactivator that involved in the activation of gene coding for 
mitochondrial protein and biosynthesis in skeletal muscle [100]. Woldt et al. has shown that 
deficiency in Rev-erbα reduced mitochondrial content, impaired mitochondrial biogenesis and 
increased autophagy [91], [96], [101]. Overexpression of Rev-erbα in vivo increases exercise 
capacity; and in vitro, Rev-erbα overexpression increases the number of mitochondria and 
improves respiratory capacity [91], [96]. Previous studies have established that PGC-1α is the 
main regulator of mitochondrial biogenesis and increased in PGC-1α in skeletal muscle up-
regulates the mitochondrial number and function [91], [96], [101]. These transcript changes were 
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observed in the muscle but not in liver or WAT suggesting that it is muscle specific regulation of 
REV-ERBα [36].   
 PGC-1α has been shown to up-regulate Bmal1 and Rev-erbα gene expression through the 
activation of RORα transcriptional activity [102], [103]. Deficiency in Pgc-1α results in similar 
metabolic syndrome as deficiency in Rev-erbα, such as a decrease in mitochondrial number and 
muscle oxidative capacity [91], [96], [104]–[106]. Moreover, PGC-1β showed similar modulation 
in circadian and metabolic regulation [103]. These findings suggest that PGC-1α, and possibly 
PGC-1β are important factors that linked circadian clock with energy metabolism through 
modulation of Rev-erbα and Rorα [103].  
The nuclear receptor coactivator PGC-1α has been shown to bind to PPAR family of 
nuclear hormone receptors as well as RORα and RORγ [76]. Moreover, Pparα transcription is 
directly regulated by CLOCK and BMAL1 [76], [97], [107], [108]. PGC-1α enhances Bmal1 
transcription by activating RORa and RORγ [12], [4], [35]. This interaction occurred as p300 
histone acyltransferase is translocated to Bmal1 promoter by PGC1α and it is dependent on the 
levels of REV-ERBα [4]. It was shown that PGC-1α protein is at a high concentration when the 
Bmal1 transcription expression is at its highest and this correlates with the repression of 
CLOCK:BMAL1 dependent transcription [4], [35]. Pgc-1α knockout mice had shown to lost their 
daily cycle pattern of their rate-limiting enzymes in oxidative phosphorylation and TCA cycle. 
Other metabolic signals such as SIRT and AMPK have shown to activate PGC-1α and alters 
PER:CRY activity [78]. These studies demonstrated the association between a variety of 
metabolic signals to REV-ERBs and PGC-1 α in regulation of energy metabolism [78]. 
Glucose metabolism by Pdk4 in skeletal muscle 
Pyruvate dehydrogenase kinase 4 (Pdk4) gene expressions is known to regulate by 
PPARα-binding upstream of its promoter [109]. PDK4 is involved in glucose metabolism by 
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inhibiting the activity of pyruvate dehydrogenase complex from converting pyruvate to acetyl-
CoA for TCA cycle. Moreover, the reduction of acetyl-CoA results in up-regulation of beta-
oxidation to make up for the decrease in acetyl-CoA. The PPARγ-regulated Pdk4 expressed 
circadian pattern in muscle and oscillate in CLOCK mutant mouse but the phase was shifted by 
12 h suggesting indirect circadian regulation due to CLOCK mutation [110]. Other than PPARγ, 
estrogen-related receptor α (ERRα) is one of the important regulators of energy metabolism in 
skeletal muscle [48], [111]. In C2C12 myotubes, overexpression of PGC-1α has been shown to 
co-activate Pdk4 transcript by binding to ERRα on the promoter and activates its gene expression, 
resulting in decrease in glucose oxidation [48]. Pdk4 is also regulated by HIF1α activity, which 
can be induced by hypoxia mimetic desferroxamine and functions as iron chelator in cell culture 
model [56].  
Circadian rhythm is disrupted in mouse strain with muscle-specific Bmal1 knockout 
[112]. Skeletal muscle in Bmal1 knockout mice has impaired insulin sensitivity, reduced GLUT4 
protein and translocation of GLUT4 [112]. Moreover, circadian gene Pdk4 gene expression is up-
regulated, inhibiting pyruvate dehydrogenase activity leading to reduced glucose oxidation in 
Bmal1 knockout mice [112]. Glycolytic substrates are mediated through other pathways [112]. 
Decreased in Pdk4 gene expression has been observed in ID rat’s skeletal muscle suggesting an 
alteration in gluconeogenesis similar to Bmal1 knockout mice [51]. These studies demonstrate 
that there are correlation between iron deficiency and circadian rhythm disruption leading to 
alteration in glucose metabolism, however, the mechanism that regulate these pathway has not 
been clearly elucidated. 
Lipid homeostasis by Srebp-1c in skeletal muscle 
The role of SREBP-1C in cholesterol and fatty acid metabolism has been extensively 
studied in liver and adipose tissue, however, studies in the skeletal muscle had just began in the 
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last decade [93], [94]. In the liver, SREBP-1c responses to circadian and nutritional cues and 
regulates genes involved in cholesterol regulation and fatty acid metabolism such as glucokinase, 
fatty acid synthase, acetyl-CoA carboxylase, and glycerol-3-phosphaste acyltransferase [94], [95]. 
In muscle cell culture, Srebp-1c gene expression decreased in diabetic-induced cells and 
increased with insulin-induced cell culture, indicating that insulin may regulate skeletal muscle 
[94]. SREBP-1C is identify to function as a transcription factor in the regulation of myogenesis 
[93]. The overexpression of SREBP-1C protein in skeletal muscle inhibits differentiation of 
myoblast to myotubes and also results in muscle degeneration both in vivo and in vitro by 
downregulating the myogenic regulatory factors (MyoD and MyoG) [93]. Overexpression of 
Srebp-1c genes has been observed in ID rat’s skeletal muscle, suggesting an alteration in 
lipogenesis [51].  
Rhythmicity in cholesterol and lipid metabolism is known to alter by feeding and fasting 
cycles, however, studies have demonstrate that the nuclear hormone receptor REV-ERBα and 
REV-ERBβ participates in circadian regulation of SREBP-1c and its target genes [50], [52], 
[113]. 
REV-ERBα involves in circadian SREBP signaling activity by targeting Insig2 gene 
expression which in turn exhibits circadian control on nuclear SREBP that are involved in 
cholesterol and lipid metabolism [50]. REV-ERBα has been shown to control the nuclear 
accumulation of SREBP and the transcription of SREBP target genes [50]. REV-ERBβ was 
demonstrated to control lipid and energy homeostasis in skeletal muscle [113]. Overexpression of 
Rev-erbβ in C2C12 myotubes have shown to decrease gene expression involved in fatty acid and 
lipid absorption (i.e. Cd36, Fabp-3, Fabp-4) and lipid metabolism (Pdk4↓1.4 fold)while increase 
lipogenic gene expression (Srebp-1c ↑2.8 fold) [52], [113].  ChIP analysis in C2C12 cells have 
shown that REV-ERBβ is recruited to Srebp-1c promoter for activation, however, REV-ERBβ 
repressed Rev-erbα promoter [52]. Moreover, treatment of C2C12 cells with hemin have shown 
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to increase gene expression of Rev-erbβ and Srebp-1c in skeletal muscles [52]. In iron deficient 
rat, Srebp1c gene expression has been shown to up-regulate in skeletal muscle [51]. These studies 
showed that heme-mediated REV-ERBs altered circadian regulation in Pdk4 and Srebp-1c which 
correlates with symptoms observed in iron deficient animals. However, detailed connection 
between iron status and these metabolic genes have not been shown. 
Iron as an essential micronutrient 
Iron is an essential micronutrient involves in metabolic and cellular processes such as 
oxygen transport, energy transformation, DNA synthesis, and heme biosynthesis [30], [114], 
[115]. The human body contains approximately 3-5 g of iron and mostly found integrated in 
hemoprotein for oxygen binding and transport such as hemoglobin and myoglobin in erythroid 
cells and skeletal muscles, respectively [116].  
Iron deficiency has affected people worldwide resulting in anemia, restlessness, muscle 
and cognitive dysfunction in adult and children. Iron deficiency has been a known problem in 
both developed and developing countries, affecting almost 30% of the world populations and 
many are women and children [31]. The demand for iron is high in adolescence due to the 
increase of blood volume and muscle mass [117]. Moreover, in general population, the 
disturbance in iron systemic and cellular homeostasis due to iron deficiency has been shown to 
enhance metabolic syndrome and diseases such as hyperglycemia, accumulation of lipid, 
cognitive dysfunction, weight gain, muscle fatigue and mitochondrial myopathy [12], [29], [33], 
[34]. Animal studies have shown that there is a correlation between iron deficiency and alteration 
in lipid and glucose metabolism due to the lowered muscle oxidative capacity, thus utilizing more 
glucose over fat [51], [118]. Iron deficiency alters metabolic homeostasis of insulin signaling 
resulting in hyperglycemia, hyperinsulinemia, and hyperlipidemia [51], [118]. Decreased in PGC-
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1α protein has been observed in iron-deficient diet, however, the mechanism for this changes is 
unknown [3], [119]. 
Iron overload leads to the generation of reactive oxygen species (ROS) which damages 
structure of DNA, protein and lipid membrane [120]. The mammalian system is efficient at 
regulating iron homeostasis, however, excess iron in individuals with inheritable disease 
hemochromatosis can result iron overload in the peripheral tissues and contribute to the 
development of metabolic disorders such as cirrhosis, cardiomyopathy as well as diabetes 
mellitus [115]. Moreover, iron toxicity also lead to neurodegenerative diseases such as 
Friedreich’s ataxia, Alzheimer’s disease and Parkinson’s disease [51], [121].   
Iron homeostasis is therefore an important cellular regulation in maintaining normal body 
function. Iron homeostasis is maintained at a systemic and cellular level by the tight regulation of 
iron uptake, storage, and export via the hormone hepcidin and iron regulatory proteins 1 and 2 
(IRP1 and IRP2). 
Systemic regulation of iron metabolism 
 There is no designated pathway to excrete iron; hence, intestinal absorption of iron must 
be regulated to provide sufficient iron to meet the demand of the body [114], [122]. In mammals, 
small amount of iron (1-2mg) is absorbed by the human body per day to replace the loss of iron 
from mucosal sloughing, loss of blood, desquamation or sweat [114], [116]. The absorption of 
iron depends on the body need which increases during growth and pregnancy while decreases 
during iron overload condition [114]. Transferrin-bound iron in the blood contributes to the 
majority of iron pool in the body and gets replenished mainly by the recycling of iron by 
reticuloendothelial macrophages via erythrophagocytosis and small portion from dietary iron 
through duodenal enterocyte.  
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 In the intestine, inorganic iron in the lumen undergo reduction from ferric to ferrous iron 
by ascorbate or ferrireductase on the intestinal membrane such as duodenal cytochrome b 
(DcytB). Duodenal enterocyte then absorb the reduced iron via divalent metal transporter 
(DMT1/SLC11A2) located on the apical membrane. The absorption of heme is not well defined 
and was hypothesized to be absorbed via heme transporter or endocytosis [123]. The enterocyte 
and macrophages contain heme oxygenase which breaks down heme and release ferrous iron 
which is then exported via ferroportin (SLC40A1). The ferrous iron then gets oxidized by 
hepaestin or ceruplasmin to form ferric iron which binds to transferring to form diferric 
transferrin for distribution to other peripheral tissues for utilization. 
 Iron trafficking in the body is regulated by the hormone hepcidin that is produced by the 
liver and is influenced by iron concentration in the body as well as conditions such as ER stress, 
inflammation, erythropoiesis and hypoxia. Hepcidin regulates the efflux of iron by regulating the 
stability of ferroportin and the inactivation of feroportin result in the retention of iron in the cells. 
Ferroportin also degrades DMT1 [124]. 
Cellular regulation of iron and Iron homeostasis 
Iron homeostasis involves complex regulatory mechanisms to meet the demand of the 
human body and to prevent toxicity from iron overloading [125].  Maintaining optimal iron level 
is crucial as disruption in iron status potentially result in cellular dysfunction and metabolic 
disorder [37], [114], [122]. In mammals, increase in serum ferritin and transferrin saturation are 
indicators of iron status. In cell culture, gene expression of Tfrc is commonly used to measure the 
increase or decrease of iron within the cell as Tfrc directly regulated by iron sensor iron 
regulatory proteins (IRPs). However, the most sensitive marker for iron status in the cell is the 
mRNA binding form of IRPs. 
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Transferrin bound to two ferric iron atoms binds to Tfrc on the cell surface where the Tf-
[Fe(III)2–TFRC] complex is endocytosed. As the complex gets endocytosed, hydrogen is pumped 
into the endosomes and this result in an increased in pH which then release of ferric iron from 
transferrin. The ferric iron gets reduced to ferrous iron by steap3 oxidoreductase before getting 
export by DMT1 into the cytosol. Apo Tf/Tfrc complex is then returned to the cell surface where 
it dissociates and initiates another round of iron uptake. DMT1 is also localized on the apical 
membrane of duodenal enterocytes where it transports ferrous iron after reduction to ferric iron 
by membrane reductases, DCYTB. Iron taken up by either Tfrc or DMT1 enters labile iron pool 
consist of ferrous iron. The iron in this pool is then sensed by iron regulatory proteins (IRPs). 
IRPs regulate the translation of mRNA coding for ferritin, ALAS, m-aconitase, ferroportin, Tfrc 
and DMT1 which are important for maintaining iron homeostasis in the cells. Iron that is not 
utilized or stored in ferritin is exported by ferroportin. Export of iron from cells is done through 
the oxidation of iron by hephaestin (membrane) or ceruloplasmin (serum).  
Iron regulatory proteins and transferrin receptor 
 Transferrin receptor (Tfrc) is responsible for the uptake of transferring bound iron found 
in the blood [114]. The uptake of iron contributes to the labile iron pool (LIP) and is used by the 
cells for DNA synthesis, mitochondrial function and heme biosynthesis [114]. The LIP also 
contributes to the iron storage in ferritin and export for use by the body via ferroportin [114]. 
These receptors and transporters are regulated tightly in the cell by iron regulatory proteins (IRP1 
and IRP2) and iron regulatory element (IRE) [37], [114]. 
 Cellular irons are maintained by IRP1 and IRP2 which bind to IRE sequence upstream or 
downstream of the target genes [115]. The interaction between IRP and IRE are important in 
maintaining the iron homeostasis, cellular iron utilization, mitochondrial biogenesis as well as 
heme biosynthesis [115], [126]. IRP biding to IRE either regulate or repress the expression of 
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proteins involved in iron import, export, usage and storage [114]. IRP binding to the 5` UTR 
inhibits transcription of mRNA while binding to 3` UTR stabilizes mRNA [114]. Ferritin and 
ferroportin contain IRE in the 5` UTR while Tfrc and Dmt1 have IRE located on the 3` UTR [37]. 
Iron status in the cell can be measured by the binding activity of IRP to IRE which is the optimal 





Figure 3: Regulation of Tfrc by IRPs during high iron and low iron condition (revised from 
Muckenthaler M.U. et al.) [37]. Iron-regulatory protein 1 and 2 (IRP1 and IRP2) are essential 
regulatory proteins for maintaining cellular iron homeostasis. IRPs bind to iron-response elements 
(IREs) in the 5′ or the 3′ untranslated region (UTR) of their target mRNAs. Ferritin (Ft), 
ferroportin (Ftn) and hypoxia-inducible factor 2α (Hif2α) contains IRE in the 5′ UTR of mRNAs. 
Transferrin receptor (Tfrc) and divalent metal transporter 1 (DMT1) has IREs in the 3′ UTR of 
mRNAs. During low iron, IRPs bind to IRE and inhibit5′ IREs translation and stabilizes 3’ IREs. 
Under high iron condition, IRP1 binds to iron and form cytosolic aconistase while IRP2 is 
degraded. IRE–IRP regulatory function to increase iron uptake by increase transferrin receptor 
and DMT1 during low iron and decrease iron storage and export by inhibiting translation of 





 Heme is an essential co-factor for cellular processes such as oxygen transport, electron 
transport, and signal transduction [127]. However, excess heme is toxic due to production of 
H2O2, and released of free iron which leads to cellular membrane damage and apoptosis [127]. 
Myoglobin may release free heme in skeletal muscle during severe ischemia-reperfusion injury 
[127].  
Heme oxygenase (encoded by Hmox-1 genes), a microsomal protein, play a critical role 
in recycling iron and maintaining cellular homeostasis under stress condition [128]. Under 
oxidative stress condition, free heme can catalyze the production of free radicals [128], [129]. 
Free iron can react in a Fenton reaction to produce highly toxic radicals derived from hydrogen 
peroxides [128], [129]. Activation of Hmox-1 is stimulated by various factors such as heme, 
ultraviolet radiation, heavy metals, hydrogen peroxides, endotoxins, and inflammation cytokines 
[128].  Heme oxygenase has been reported to be induced in rat skeletal muscle following 
exhaustive exercise, stimulation by electricity and hemin treatment [127].  
To remove the pro-oxidant caused by free heme, heme oxygenase breaks down free heme 
into free iron (Fe2+), carbon monoxide (CO) and biliverdin [127]–[129].  Biliverdin and its 
reduced form bilirubin are efficient free radical scavengers that behave as anti-oxidants [127]. 
Moreover, CO functions as vasodilator. The importance of heme oxygenase in cyto-proctection 
and heme metabolism may be one of the indicators of stress within the cells due to effect of iron 
chelation or iron loading treatment. 
C2C12 in circadian in vitro model  
In mammals, skeletal muscle is composed of several muscle fibers (i.e. myocytes) and the 
formation involves the differentiation of myoblast (embryonic progenitor cells) into myotubes 
during fetal and postnatal development. During muscle damage or degradation, skeletal muscle 
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resident stem cells, known as the satellite cells, gets activated by entering the cell cycle, 
proliferate and form myoblasts [130]–[132]. The activation of satellite cells is due to extracellular 
signal associated with damage in skeletal muscle, contribute to the pool of myoblasts available 
and provide differentiation-competent myoblast for growth and repair [130]–[132]. These 
myoblasts will replace the damaged muscle fibers by differentiating and fusing with other 
myofibers through the process of myogenesis [130]–[132].  
The C3H mice dystrophic thigh muscle-derived C2C12 mouse myoblast has the 
capability to differentiate into myotubes which is closer replication of the physiological state of 
muscle cells by displaying the increase in metabolic flux and mitochondrial respiration [133], 
[134]. C2C12 is an immortalized cell line derived from muscle progenitor cells [135]. They can 
differentiate rapidly, forming contractile myotubes and producing characteristic of muscle 
proteins. The advantage of examining circadian metabolism via in vitro method is that it allows 
the elimination of upstream factors that impact the circadian regulation such as diet and hormonal 
regulation [133]. Nevertheless, the purpose of study is to further comprehend the cellular 
regulation at the tissue and organism level and therefore, provides a holistic portrait of physiology 
and metabolism [133].  
Objectives and hypothesis 
These findings lead to the proposed examination on impact of iron depletion and 
overloading on circadian and metabolic gene expression in C2C12 synchronized myoblast which 
model the physiological state of proliferating muscle cells. The relationship of iron status and 
regulation of Bmal1 and Rev-erbα gene expression may reveal the impact of iron status on 
circadian rhythm and its related metabolic gene expression specific to skeletal muscle cells.  
Our objective was to further examine and characterize the effect of iron status on the 
alteration in circadian and metabolic gene expression in synchronized C2C12 myoblast in vitro. 
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Our central hypothesis was that iron chelation and iron loading would alter circadian and 
metabolic gene expression (in mitochondrial, myogenesis, macronutrient metabolism) in C2C12 
myoblast. Furthermore, we hypothesized that chelation and loading of iron would alter 
mitochondrial function and oxidative capacity. Thus, the results presented herein provide insight 









Maintenance of C2C12 myoblast cells 
Mouse myogenic cell line C2C12 was obtained from a subclone of dystrophic thigh 
muscle of C3H mice C2C12 (ATCC®; CRL­1772™, Manassas, VA). C2C12 is an immortalized 
cell line derived from muscle progenitor cells (also known as muscle satellite cells) [135]. These 
muscle satellite cells enter cell cycle and proliferate into myoblast which replace damaged cells 
by fusing with each other via differentiation [133]–[135].  
C2C12 myoblast cells were maintained in complete media containing Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 4.5g/L glucose, 2.5 mM L-glutamine and sodium 
pyruvate (Cellgro; Catalog # 10-013-CV; Henderson, VA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Atlanta Bio; Catalog # S11150H, Lawrenceville, GA), 2 
mM L-glutamine (Cellgro; Catalog # 25-005-c1; Henderson, VA) and penicillin-streptomycin in 
antibiotic-antimycotic solution containing 100 IU penicillin, 100 μg/mL streptomycin, and 0.25 
μg/mL amphotericin B with 8.5 g/L NaCl (Cellgro; Catalog # 30-004-c1;Henderson, VA). The 
cells were grown for no more than 80% confluence in 100 mm plate in 10 mL of complete media 
and maintained at 37°C in a humidified incubator with 5% CO2 supply. Cells were passage up to 
25 times, and frequency of every 48 hours at 1:20 dilution or every 36 hours at 1:40 dilution. To 
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determine the concentration of viable cells, cells were stained with 0.40% trypan blue and 
counted under the microscope for unstained live cells; dead cells are stained blue. 
In vitro circadian assay 
 Synchronized C2C12 myoblasts and myotubes were used as models for studying 
circadian rhythm by serum shock using a method described by Peek, CB et al [13] [136]. 
For in vitro circadian study in myoblast, 1x105 cells/mL C2C12 myoblast cells were 
seeded in 6-well plate in complete media and incubated for 24 hours (grown to 80-90% 
confluence). After 24 hours, the cells were serum shock with DMEM supplemented with 50% 
heat-inactivated donor horse serum (HS) for 2 hours (Atlanta Bio, Catalog #S12150H; 
Lawrenceville, GA). Media was switched back to complete media after serum shock and 
treatments (described below) were introduced for 18 or 24 hours followed by RNA and protein 
extraction. 
For myotubes in vitro experiments, myoblast cells were seeded in a 6-well plate at 1 x 
105 cells/mL in 10% FBS supplemented DMEM media and incubated for 24 hour (grown to 80-
90% confluence). After 24 hours, media was replaced with DMEM supplemented with 2% heat-
inactivated horse serum to facilitate cell differentiation and media was replaced every other day. 
Differentiation medium (DM) consisted of DMEM supplemented with 4.5 g/l glucose, 2% heat-
activated horse serum (Atlanta Bio; catalog # S12195H,Lawrenceville, GA), 2.5 mM glutamine, 
1 mM sodium pyruvate, and 100 IU penicillin and 100ug/mL streptomycin. After 5 days in DM, 
C2C12 myotubes were serum shock with DMEM supplemented with 50% horse serum for 2 
hours. Treatments (described below) were introduced at time 24 hour after changing to 0.5% 
horse serum + DMEM. Total RNA and protein were harvested at 18 hour after treatment 
following serum stimulation. 
DFO, FAC and hemin treatments  
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C2C12 myoblast and myotube cells were treated after serum shock for 18 hours with iron 
chelator using 100 μM deferoxamine (DFO) mesylate salt (Sigma-Aldrich; Catalog # D9533, St. 
Louis, MO). Iron loading treatment used were 100 μM iron using ferric ammonium citrate (FAC) 
(Sigma-Aldrich; Catalog # F5879, St. Louis, MO) solubilized in dimethylsulfoxide (DMSO) 
(Sigma-Aldrich; Catalog # D8418, St. Louis, MO) and 100 μM of iron from hemin (Frontier 
Scientific; Catalog # H651-9, Logan, UT). To ensure diurnal rhythmicity in C2C12 myoblasts, 
these cells were treated and harvested every 6 hours for a period of 24 hours. C2C12 myotubes 
were treated for 18 hours with 200 µM DFO, 200 µM FAC, and 50 µM hemin. The gene 
expression of Tfrc is used as a measurement for iron depletion or iron loading. 
RNA extraction 
To study the alterations in circadian and metabolic gene expression following treatments, 
total RNA was extracted from C2C12 myoblasts. Media was aspirated and C2C12 adherent cells 
were lysed by resuspension with 1 mL RNA STAT-60 (Tel-test, Inc.; Catalog # CS-502, 
Friendswood, TX) and transfer to 1.7 mL sterile microcentrifuge tubes. The lysed cells were 
incubated at room temperature for 5 minutes to allow dissociation of ribonucleoprotein 
complexes. After 5 minutes incubation, 200 μL CHCl3 was added (Sigma; Catalog # C2432, San 
Francisco, CA) and shaken vigorously for 30 seconds to homogenize the cells. The cells were 
incubated at room temperature for 3 minutes and following the incubation, the cells were 
centrifuge at 12,000xg for 15 minutes at 4°C. The protein disassociated into the organic phase 
and the RNA is in the aqueous phase. The aqueous phase was transferred into new 1.7 mL micro-
centrifuge tubes and 500 μL of isopropanol was added and vortex briefly. RNA was precipitated 
overnight at -80°C and followed by centrifugation at 12,000xg for 30 minutes at 4°C. Supernatant 
was decant and the RNA pellet was wash with 75% ethanol and centrifuge at 12,000xg for 10 
minutes at 4°C. Ethanol was discard and pellet was air dried for 7 minutes. The RNA pellet was 
incubated in DEPC water (diethyl pyrocarbonate) for 30 minutes before resuspending. The 
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concentration and purity were determined using nanospectrometer Nanodrop-1000 (Thermo 
Scientific; Wilmington, DE). The RNA integrity was determined by 1% agarose gel 
electrophoresis (Sigma; Catalog #A9539, San Francisco, CA) in a solution of 1xTAE [40 mM 
Tris-acetate acid and 1 mM ethylenediaminetetraacetic acid (EDTA)] using a 1:10000 dilution of 
Gel Star Nucleic Acid Gel Stain (Lonza; Catalog # 50535; Rockland, ME). 
cDNA synthesis for gene expression analysis 
cDNA was synthesized from C2C12 total RNA for analysis of gene expression via 
quantitative polymerase chain reaction (qPCR). Total RNA (2 μg) was treated with DNase I 
(Roche Applied Science; Catalog # 04716728001, Indianapolis, IN) at 37°C for 30 minutes 
followed by heat inactivation at 75°C for 10 minutes and soak at 4°C in a BioMetra T-Gradient 
thermocycler (Biometra,; Goettingen, Germany). DNase I treated RNA was then reverse-
transcribed with SuperScript™ II Reverse Transcriptase (Invitrogen; Catalog # 18064071, 
Carlsbad, CA), random hexamers (Roche Applied Science; Catalog # 11034731001, Indianapolis, 
IN), 1 mM dNTP mix (Promega Catalog # U1240, Madison, WI), and 10 mM DTT (Invitrogen, 
Carlsbad, CA). Samples were incubated at 25°C for 10 minutes, 42°C for 50 minutes, and 72°C 
for 15 minutes and soaked at 4°C in a thermocycler. cDNA was used for qPCR analysis or stored 
at -20°C until future use up to six months. 
Quantitative PCR analysis 
Quantitative polymerase chain reaction (qPCR) was used to examine alterations in gene 
expression in response to treatment conditions. Each reaction was performed in triplicate with a 
final volume of 10 μL per reaction. Each reaction contained SYBR Green (SA Biosciences; 
Catalog # 4368706, Frederick, MD), 50 ng cDNA, and 2.5 μM of the primer mix obtained from 
Integrated DNA Technology (IDT, Coralville, IA). PrimerExpress2.0 software (Applied 
Biosystems; Foster City, CA) was use to design qPCR primers and the sequences were designed 
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with amplicon spanning an intron whenever possible. Reactions were performed on a 
MULTIMAX 384 well PCR Plate in triplicate (Bioexpress, Catalog # T-3138-1, Kaysville, UT) 
using a 7900HT Fast Real-time PCR System (Applied Biosystems, Foster City, CA). mRNA 
expression levels were analyzed using relative quantification 2-ΔΔCT method analyzed via SDS 2.4 
(Applied Biosystems; ABI software, Foster City, CA) and Cq values where obtained for the genes 
measured [137], [138]. 
  Accurate analysis of circadian and metabolic gene expression requires appropriate 
housekeeping genes for normalization. Housekeeping genes 36b4, β-actin, Cyclo, Hprt1, Rpl19 
mRNA expression were assessed using real-time qPCR. The determination of housekeeping gene 
was calculated via NormFinder using log of CT values to plot the most stable genes for C2C12 









XF96 Seahorse Assay 
Seahorse XF96 analyzer measured mitochondrial respiration and glycolysis in living 
cells. The Seahorse XF technology has sensor that measures both oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR). For our study purpose, mitochondria 
respiration was analyze and OCR was measure via mitochondria stress test. 
Seeding C2C12 in Seahorse XF96 mircoplate 
C2C12 myoblast cells were seeded in a Seahorse 96 well XF cell culture microplate 
(Seahorse Bioscience, Catalog # 101085-004; North Billerica, MA) at 80 μL in complete media at 
final concentration of 1x105cells/mL. Background correction wells (A1, A12, H1, H12) are fill 
with 100 μL complete media only. Plate is rest in the cell culture hood at room temperature for 
one hour to allow even distribution of cells before incubating at 37°C for 24 hours. After 24 
hours, media is replaced with synchronization media (50% horse serum/50%DMEM) for 2 hours. 
After serum shock, media was replaced with complete media and cells are treated with 100 μM 
DFO, FAC and hemin treatments (described above) for 18 hours before running Mito stress test.  
XF96 Assay Cartridge and Assay Media Preparation 
XF96 sensor cartridge (Seahorse Bioscience, Catalog # 101085-004; North Billerica, 
MA) has solid sensors for oxygen consumption and extracellular acidification which also contains 
four ports per well for compounds injection during the analysis. The day before running assay, 
the XF96 sensor cartridge is hydrated. Each well of the Utility Plate is filled with 200 μL of 
Seahorse XF Calibrant. Sensor Cartridge (Seahorse Bioscience, Catalog # 100840-000; North 
Billerica, MA) is gently lowered onto the Utility Plate submerging the sensors in XF Calibrant. 




XF base medium (Seahorse Bioscience, Catalog # 102353; North Billerica, MA) was pre-
warmed in 37°C water bath until ready to use. To make mito stress test assay medium, in 150 mL 
of XF base media, 25 mM of d-glucose (Sigma-Aldrich; # G7528, St. Louis, MO), 1 mM sodium 
pyruvate (Sigma-Aldrich; # S8636, St. Louis, MO) and 2 mM L-glutamine (Life Technologies; 
Catalog #25030-081, Carlsbad, CA) were added and adjusted  pH to 7.4 using 1 M NaOH.  
After 18 hours of treatments of C2C12, media was removed and microplate was gently 
washed three times with 200 μL of pre-warmed mito stress test assay medium. Finally, the cells 
were incubate with 175 μL cell mito stress test assay medium in 37°C incubator without CO2 for 
1 hours to allow cells to equilibrate with the assay medium and ready for XF96 Seahorse Assay.  
Mitochondrial Respiration Measurement Using XF96 Cell Mito Stress Test Kit 
XF96 Mito stress test kit (Seahorse Bioscience; Catalog # 101706-100, MA) was utilized. 
Compounds for mito stress test were added to pre-warmed mito stress test assay medium prior to 
loading sensor cartridge. The mito stress test compounds are 25 μL of 1 μM oligomycin, 1 μM 
FCCP (carbonilcyanide p-triflouromethoxyphenylhydrazone) and 1μM rotenone/antimycin A. 
The compounds were loaded in proper column with a multi-channel pipette according to assay lay 
out into ports A, B, and C respectively. The sensor cartridge with compounds was loaded on 
XF96 Extracellular Flux Analyzer for calibration prior to Mito stress assay. Once calibration 
process is done, microplate containing C2C12 cells was loaded onto the XF96 Extracellular Flux 
Analyzer and start the mito stress test assay. The compounds were loaded sequentially as 
described in Table 3.  
Oligomycin is an inhibitor of ATP synthase (complex V), FCCP is a mitochondrial 
uncoupler, and antimycin A/rotenone are electron transport inhibitor (complex III and complex I, 
respectively). Mito stress test reveals the key parameters of mitochondrial function by measuring 
the oxygen consumption rate (OCR) in the media to assess basal respiration, ATP turnover, 
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proton leak and maximal respiration. The rate of OCR is proportional to mitochondrial 
respiration. The test was carried out by sequentially loading of Oligomycin, FCCP and 
rotenone/antimycin into port A, B and C respectively to obtain OCR measurement using XF96 
WAVE program (Seahorse Biosciences, Software Version 2.2 Wave controller, MA). Small 
changes in O2 level and pH can be readily detected by Seahorse analyzer. Proteins were extracted 
from the microplate and concentrations were obtained via BCA assay. OCR measurements were 










Cytosolic proteins were extracted for normalization of protein concentration with OCR 
from Seahorse XF96 mitochondrial stress test. XF buffer media was removed from XF96 
microplate and the cells were gently washed three times with ice-cold phosphate buffered saline 
(PBS) (Cellgro, Herndon, VA; Catalog # 21-031-CV). Cells were resuspended in cell lysis buffer 
(20 mM HEPES pH 7.4, 10 mM sodium pyrophosphate, 50 mM sodium fluoride, 50 mM β-
glycerol phosphate, 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM guanosine 
triphosphate (GTP), 1 mM sodium orthovanadate, and 0.5% v/v NP-40) containing protease 
inhibitors (0.1 mg/mL leupeptin, 0.1 mg/mL pepstatin, 0.25 mg/mL soybean trypsin inhibitor, 0.2 
mM phenylmethylsulfonylfloride, and 0.1 mM MG-132), 1 mM citrate, and 1 mM dithiothreitol 
(DTT). Samples were incubated on ice on a shaker for 1 hour. After 1 hour, protein 
concentrations of cell extracts were measured using Pierce™ BCA Protein Assay Kit (Thermo 
Sci, Catalog # 23227; Grand Island, NY) using Synergy HT microplate reader (Biotek; Winooski, 
VT). 
Statistical Analysis 
Data from C2C12 cells were analyzed with either one-way ANOVA or student’s T-test 
using SPSS software version 17.0 (IBM-SPSS, Chicago, IL) to determine statistically significant 
changes. Gene expression between control and treatment groups at same time point or control at 
0h and treatment group at different time point was determined using student’s t-test. Dose 
response experiment and mitochondrial stress test were analyzed with one-way ANOVA. All 








Effects of treatment in C2C12 Myoblast 
Effects of DFO, FAC, and hemin concentrations on Tfrc and Hmox-1gene expression 
To determine the appropriate concentration of DFO, FAC and hemin, C2C12 cells were 
treated in varying concentrations for 18 h. Based on various literatures that studied Tfrc gene 
expression with effect of iron source and iron chelator treatments, treatment time ranges from 6, 
12, 16, 18 and 24 h [3], [140]–[143]. The optimal time ranges from 12-24 h for observation of  
significant changes of Tfrc gene expression [140]. Studies on cell culture on DFO, FAC and 
hemin treatment commonly ranges from 50-200 μM for DFO, while FAC is 20-500 μM and 
hemin is 10-200 μM and ranging period from 16 h-24 h treatment [3], [141]–[146]. 
The dose response experiment measured Tfrc and Hmox-1 gene expression after 18 h of 
treatment. C2C12 myoblasts were treated with different concentration of DFO (0, 50, 100 and 
200 μM) and significant differences were observed with Tfrc gene expression in 100 μM (p = 
0.025) and 200 μM (p = 0.012) treatment (Figure 4A). No significant changes in Hmox-1 was 
observed, however, the gene expression was trending upward (Figure 4A). Incubating C2C12 
cells in 100 μM is sufficient to significantly induced Tfrc gene expression.  
Tfrc gene expression in FAC (0, 100, and 200 μM) treated cells was trending downward 
but no statistical significant different was observed (Figure 4B). Hmox-1 gene expression was 
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upregulated by 3- and 2.9- fold in 100 μM and 200 μM. Higher concentration of FAC (400 μM) 
resulted in cell death in C2C12 myoblast (data not shown due to cell death). 100 μM of FAC was 
used in the study based on 40% decreased in Tfrc gene expression despite insignificant statistical 
difference. 
In hemin (0, 100, 200, and 400 uM) treated cells, there was a significant repression of 
Tfrc gene expression at 100 μM (p =0.014), 200 μM (p = 0.005) and 400 μM (p = 0.002) (Figure 
4C). As expected, high induction of Hmox-1 gene expression was observed in hemin treated cells 
(100 μM: p = 0.004; 200 μM: p = 0.000; 400 μM: p = 0.000). Interestingly, the induction of 
Hmox-1 went slightly down in 400 μM hemin when compared to 200 μM treated cells.  
These findings demonstrated that DFO and hemin are effective to stimulate a change in 
Tfrc gene expression. Therefore, treatment concentration for the study was decided at 100 μM for 
DFO, 100 μM FAC and 100 μM hemin. FAC treatment needs further validation by measurement 
of iron regulatory protein (IRP) RNA binding activity to ensure iron loading. Moreover, cell 
viability is needed to ensure the changes in gene expression are not resulted from cell death. 
Effect of DFO, FAC, and hemin on Alas1, Bmal1, Rev-erbα and Tfrc gene expression 
 To determine the treatment effect of iron chelator (DFO) and iron sources (FAC and 
hemin) on circadian rhythmicity in C2C12. Cells were harvest at every 6 h for a period of 24 h 
starting from time of treatment for qPCR analysis. 
In DFO treated cells, no change in oscillation of Alas1 gene expression however, there 
was a 2.6-fold increase of peaked ZT12 (p= 0.003) (Figure 5A). Bmal1 and Rev-erbα gene 
expression exhibit circadian oscillation and treatment with DFO significantly increased the 
amplitude of the oscillation. Regulation of Bmal1 gene expression is still in phase and was 
significantly regulated at ZT24 (p = 0.011) (Figure 5B). Rev-erbα gene expression is trending 
toward a constant increased and significantly up-regulated at ZT18 (p = 0.028) and ZT24 (p = 
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0.025) (Figure 5C). Tfrc gene expression is upregulated at ZT12 (p = 0.017) and peaked at ZT18 
(p = 0.019). Despite a slight decrease, Tfrc was still significantly up-regulated at ZT24 (p = 
0.030), indicating higher demand of iron by the cell (Figure 5D). 
In FAC treated cells, Alas1 gene expression loses rhythmicity and significantly regulate 
over 24 h period (p ≤ 0.05) (Figure 6A). Bmal1 gene expression was similar to control cells at 
ZT6 but trend toward repression in gene expression from ZT12 – ZT24 (Figure 6B). Despite the 
downward trend in Bmal1 from ZT12 to ZT24, the gene expression was higher than the control at 
ZT12 (p = 0.005) and ZT18 (p = 0.013). The oscillation of Rev-erbα is out-of-phase by 6 h 
despite similar amplitude and trough (ZT12: p = 0.017) (Figure 6C). Tfrc gene expression was 
trending downward at ZT6 and ZT 12 by 40%, however, at ZT18 and ZT 24 (p = 0.025), Tfrc 
gene expression in FAC treated cells was similar to the control (Figure 6D).  
In hemin treated cells, Alas1gene expression was down regulated over the 24 h period, 
and was significantly different from the control at ZT6 (p = 0.010) (Figure 7A). Bmal1gene 
expression was down regulated over 24 h period, however, no significant difference was observed 
(Figure 7B). In the case of Rev-erbα gene expression, the oscillations in mRNA between control 
and hemin treated cells had similar period, however, hemin treated cells have higher amplitude at 
ZT12 (p = 0.022) and lower trough at ZT6 than the control (Figure 7C). Tfrc gene expression 
was significantly repressed at ZT6 (p = 0.024), ZT12 (p = 0.011), ZT18 (p = 0.013),  and ZT24 (p 
= 0.014) (Figure 7D).  
These results confirm our hypothesis that iron status based on changes in Tfrc gene 
expression regulates circadian (Bmal1 and Rev-erbα) and metabolic (Alas1) gene expression. In 
FAC treated cells, Tfrc gene expression was not significantly repressed, however, changes 
circadian rhythm in Alas1, Bmal1 and Rev-erbα were observed.  
Effect of DFO, FAC, and hemin on circadian gene expression 
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 Core circadian clock gene expression in C2C12 treated cells was assessed by qPCR. 
After 18 h of iron chelator and iron loading treatment, cells were harvested for RNA extraction 
and qPCR analysis to measure circadian gene Bmal1, Clock, Cry1, Per2, Rev-erbα, Rev-erbβ and 
Rorα expression.  
 At ZT18, Bmal1 and Rev-erbα gene expression was significantly up-regulated in DFO 
treated cells by 1.7- (p = 0.010) and 3.4- (p = 0.010) folds respectively (Figure 8A). Per2 gene 
expression was down-regulated (p =0.039). No significant change was observed in Clock, Cry1, 
and Rev-erbβ. Interestingly, in DFO treated cells, Rorα was increased by 22.4-fold (p = 0.001).  
 In FAC treated cells, Rev-erbβ gene expression was down-regulated at ZT18, however, 
only changes in Rev-erbβ (p = 0.020) were statistically significant (Figure 8B). No significant 
change was observed in Bmal1, Clock, Cry1, and Per2 gene expression (Figure 8B). In hemin 
treatment at ZT18, no significant change was observed in Bmal1, Clock, Cry1, Per2, Rev-erbα, 
Rev-erbβ and Rorα gene expression (Figure 8C). Interestingly, despite no statistically significant 
result, Rev-erbα and Rev-erbβ gene expression were trending towards repression, which is similar 
to treatment with FAC.  
Effect of DFO, FAC, and hemin on iron metabolism, heme biosynthesis and mitochondrial 
gene expression 
 To determine the effect of iron treatment and iron chelation on gene expression involves 
in energy metabolism, mitochondrial biogenesis, heme biosynthesis, and iron metabolism, Pgc1α, 
Pgc1β, Alas1, Hmox-1, and Tfrc gene expression were analyzed via qPCR. 
In DFO treated cells, Pgc1α (p = 0.006) and Tfrc (p = 0.002) gene expression were 
significantly up-regulated at ZT18 (Figure 9A). Interestingly, Pgc1β gene expression was 




In FAC treated cells, Pgc1α (p = 0.009) and Alas1 (p = 0.011) gene expression were 
significantly up-regulated while gene expression was significantly repressed (Figure 9B). 
However, no significant change in Pgc1β, Hmox-1 and Tfrc was observed. 
In hemin treated cells, Hmox-1 (p = 0.012) was significantly up-regulated while Pgc1β (p 
= 0.032) gene expression was significantly repressed (Figure 9C). As expected, Tfrc (p = 0.015) 
is down regulated with hemin treatment. However, no change in Pgc1α and Alas1 gene 
expression was observed. 
Effect of DFO, FAC, and hemin on metabolic gene MyoD, Pdk4 and Srebp1c expression 
 MyoD, Pdk4 and Srebp-1c are genes that are involves in skeletal muscles differentiation, 
glucose metabolism and lipid metabolism, respectively. The changes in genes expression were 
assessed by qPCR.   
In DFO treated cells, a dramatic increase in Pdk4 (p = 0.004) gene expression with 9.9 
fold was observed at ZT18 (Figure 10A). No change in MyoD and Srebp-1c gene expression was 
observed. 
 In FAC treated cells, MyoD (p = 0.05), Pdk4 (p = 0.024) and Srebp-1c (p = 0.019) gene 
expression were significantly repressed at ZT18 (Figure 10B). In hemin treated cells, MyoD (p = 
0.017) and Pdk4 (p = 0.052) gene expression were significantly repressed at ZT18 (Figure 10C). 
Despite insignificant difference, Srebp-1c gene expression was trending towards repression. 
Effect of DFO, FAC, and hemin on maximal mitochondria respiration capacity 
To study the effect of iron status on mitochondrial function in C2C12 myoblast, XF96 
seahorse mitochondrial stressed test was utilized. Cell density (5k, 10k and 20k) and oligomycin 
concentration (0, 0.5, 1, and 2 μM) were optimized (Figure 11A & 11B). Cell density at 10k and 
1 μM of oligomycin were used for the study. Next, FCCP concentration (0, 0.75, 1.5, 3, 4.5 and 6 
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μM) were optimized (Figure 12). The optimal concentration for FCCP was 0.75 μM. 
Mitochondrial stress tests were performed on C2C12 myoblast treated with DFO, FAC and hemin 
(Figure 13). Despite insignificant difference, oxygen consumption rate (OCR) for DFO treated 
cells were trending downward compare to control cells. FAC (p = 0.000) and hemin (p = 0.011) 
treated cells experienced significant increase in OCR (Figure 13).  
Effects of treatment in C2C12 Myotubes 
Effect of DFO, FAC, and hemin on circadian gene expression 
Core circadian clock gene expression in C2C12 myotubes treated cells was assessed by 
qPCR. After serum shock, cells were treated at ZT6. After 18 h of iron chelator and iron loading 
treatment, cells were harvested at ZT24 for RNA extraction and qPCR analysis to measure 
Bmal1, Rev-erbα, Rev-erbβ and Rorα gene expression.  
 At ZT24, Bmal1 and Rorα gene expression was significantly up-regulated in DFO treated 
cells by 1.7- (p = 0.043) and 3.4- (p = 0.001) folds respectively (Figure 14A). No significant 
change was observed in FAC or hemin treatment in these genes except for an increased in Rev-
erbα (p = 0.020) with hemin treatment. 
Effect of DFO, FAC, and hemin on iron metabolism, heme biosynthesis and mitochondrial 
gene expression 
To determine the effect of iron treatment and iron chelation on gene expression involves 
with energy metabolism, mitochondrial biogenesis, heme biosynthesis, and iron metabolism, 
Pgc1α, Pgc1β, Alas1, Mfrn2, Hmox-1, and Tfrc gene expression was analyzed via qPCR. 
Pgc-1α gene expression was significantly inhibited in DFO (p = 0.000) and hemin (p = 
0.000) treatment ZT24 (Figure 14B). No changes in Alas1 and Mfrn2 gene expression was 
observed except for Alas1 gene expression in hemin treated cells. Tfrc was significantly 
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expressed in DFO (p = 0.006) and inhibited in FAC (p = 0.000) and hemin (p = 0.000) treatment. 
Hmox-1 was upregulated with hemin treatment (p = 0.003) (Figure 14C). 
Effect of DFO, FAC, and hemin on metabolic gene MyoD, Fasn and Srebp1c expression 
 MyoD, Fasn and Srebp-1c are genes that are involved in skeletal muscles differentiation, 
glucose metabolism and lipid metabolism, respectively. The changes in genes expression were 
assessed by qPCR.  
 MyoD gene expression was significantly down regulated in all treatment (DFO, p = 
0.024; FAC, p = 0.038, Hemin, p = 0.003) (Figure 14D). Intriguingly, Fasn gene expression was 
upregulated with FAC treatment but went down with hemin. No change in Srebp1c gene 














































Figure 4: Dose dependent response of (A) DFO, (B) FAC and (C) hemin over 18 h treatment 
with C2C12 myoblast in complete media. Tfrc and Hmox-1 mRNA abundance was determined by 
qPCR. All treatments concentration were compared with control. Data is representative of at least 
three independent experiments conducted in duplicate and are expressed as fold changes ± SEM. 
Significant difference was determined using one-way ANOVA; Significance is set at P < 0.05 
































































































































































































Figure 5.1: Diurnal rhythmicity of (A) Alas1 (B) Bmal1 (C) Rev-erbα and (D) Tfrc gene 
expression in C2C12 myoblasts post serum shock. C2C12 myoblasts were treated with DFO after 
serum shock for a period of 24 h and RNA was harvested every 6 h. mRNA abundance was 
measured by qPCR and normalized to 36b4. Data is representative of three independent 
experiments conducted in duplicate and are expressed as fold changes ± SEM. Significant 

























































































































































Figure 5.2: Diurnal rhythmicity of (A) Alas1 (B) Bmal1 (C) Rev-erbα and (D) Tfrc gene 
expression in C2C12 myoblasts post serum shock. The line graph (from Figure. 5.1) represents 
gene expression of treatment compared to 0h control. Bar graph is a representative of untreated 
control compare with treated cells at the same time point. C2C12 myoblasts were treated with 
DFO after serum shock for a period of 24 h and RNA was harvested every 6 h. mRNA abundance 
was measured by qPCR and normalized to 36b4. Data is representative of three independent 
experiments conducted in duplicate and are expressed as fold changes ± SEM. Significant 
different was determined using student’s t-test. *P < 0.05 when compared to untreated control at 





























































































































































Figure 6.1: Diurnal rhythmicity of (A) Alas1 (B) Bmal1 (C) Rev-erbα and (D) Tfrc in C2C12 
myoblasts post serum shock. C2C12 myoblasts were treated with 100 μM FAC after serum shock 
for a period of 24 h and RNA was harvested every 6 h. mRNA abundance was measured by 
qPCR and normalized to 36b4. Data is representative of three independent experiments conducted 
in duplicate and are expressed as fold changes ± SEM. Significant different was determined using 


























































































































































Figure 6.2: Diurnal rhythmicity of (A) Alas1 (B) Bmal1 (C) Rev-erbα and (D) Tfrc gene 
expression in C2C12 myoblasts post serum shock. The line graph (from Figure. 6A) represents 
gene expression of treatment compared to 0h control. Bar graph is a representative of untreated 
control compare with treated cells at the same time point. C2C12 myoblasts were treated with 
FAC after serum shock for a period of 24 h and RNA was harvested every 6 h. mRNA abundance 
was measured by qPCR and normalized to 36b4. Data is representative of three independent 
experiments conducted in duplicate and are expressed as fold changes ± SEM. Significant 
different was determined using student’s t-test. *P < 0.05 when compared to untreated control at 
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Figure 7.1: Diurnal rhythmicity of (A) Alas1 (B) Bmal1 (C) Rev-erbα and (D) Tfrc in C2C12 
myoblasts post serum shock. C2C12 myoblasts were treated with 100 μM hemin after serum 
shock for a period of 24 h and RNA was harvested every 6 h. mRNA abundance was measured 
by qPCR and normalized to 36b4. Data is representative of three independent experiments 
conducted in duplicate and are expressed as fold changes ± SEM. Significant different was 

























































































































































Figure 7.2: Diurnal rhythmicity of (A) Alas1 (B) Bmal1 (C) Rev-erbα and (D) Tfrc gene 
expression in C2C12 myoblasts post serum shock. The line graph (from Figure. 7A) represents 
gene expression of treatment compared to 0h control. Bar graph is a representative of untreated 
control compare with treated cells at the same time point. C2C12 myoblasts were treated with 
FAC after serum shock for a period of 24 h and RNA was harvested every 6 h. mRNA abundance 
was measured by qPCR and normalized to 36b4. Data is representative of three independent 
experiments conducted in duplicate and are expressed as fold changes ± SEM. Significant 
different was determined using student’s t-test. *P < 0.05 when compared to untreated control at 
























































































































































































Figure 8: Circadian Bmal1, Clock, Cry1, Per2, Rev-erbα, Rev-erbβ and Rorα gene expression in 
C2C12 synchronized myoblast at 18h post serum shock treated with (A) 100 μM DFO (B) 100 
μM FAC (C) 100 μM hemin for 18h post serum shock. Gene expression was measured by qPCR 
and normalized to 36b4. Data is representative of three independent experiments conducted in 
duplicate and are expressed as fold changes ± SEM. Significant different was determined using 
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Figure 9: Metabolic gene expression in C2C12 synchronized myoblast treated (A) 100 μM DFO 
(B) 100 μM FAC (C) 100 μM hemin. Genes involves in mitochondrial biogenesis (Pgc1α, 
Pgc1β), heme biosynthesis (Alas1), and iron metabolism (Hmox-1 and Tfrc ) was analyzed via 
qPCR. Gene expression was measured by qPCR and normalized to 36b4. Data is representative of 
three independent experiments conducted in duplicate and are expressed as fold changes ± SEM. 
Significant different was determined using student’s t-test; *P < 0.05 when compared to untreated 







































































































































Figure 10: Metabolic gene expression in C2C12 synchronized myoblast treated with (A) 100 μM 
DFO (B) 100 μM FAC (C) 100 μM hemin for 18h post serum shock. Gene expression was 
measured by qPCR and normalized to 36b4. Data is representative of three independent 
experiments conducted in duplicate and are expressed as fold changes ± SEM. Significant 
different was determined using student’s t-test; *P < 0.05 when compared to untreated control at 









































Figure 11: (A) Cell density and (B) oligomycin concentration optimization. Oxygen consumption 
rate (OCR) in C2C12 myoblasts was measured using Extracellular flux analyzer XF96 Seahorse 
in response to variation of Oligomycin concentration (0 μM, 0.5 μM, 1, μM, and 2 μM) , FCCP (3 










































































Figure 12: FCCP concentration optimization. Oxygen consumption rate (OCR) in C2C12 
myoblasts was carried out using Extracellular flux analyzer XF96 Seahorse in response to the 
addition of Oligomycin (1 μM), FCCP (0 μM, 0.75 μM, 1.5 μM, 3 μM, 4.5 μM and 6 μM), 















































Figure 13: XF96 Seahorse mitochondria stress test in C2C12 myoblasts. Oxygen consumption 
rate (OCR) in C2C12 myoblasts was carried out using Extracellular flux analyzer XF96 Seahorse 
in response to the addition of Oligomycin (1 μM), FCCP (1 μM), Antimycin A and Rotenone (1 
μM). Cells were plated at 10k/well. Significant difference was determined using one-way 
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Figure 14: Circadian and metabolic gene expression in C2C12 synchronized myotubes treated 
with 200 μM DFO, 200 μM FAC, and 50 μM hemin. (A) Circadian (B) energy and iron 
metabolism, (C) Hmox-1 and metabolic genes were analyzed. Cells were treated at ZT6 and 
harvest at ZT24 after 18 hours of treatment. Gene expression was measured by qPCR and 
normalized to 36b4. Data is representative of three independent experiments conducted in 
duplicate and are expressed as fold changes ± SEM. Significant different was determined using 
























































































The existence of circadian clock in metabolic tissues such as liver, pancreas, adipose and 
skeletal muscle indicates the important role circadian rhythm plays in metabolic regulation. The 
purpose of this study is to (I) determine the effect of iron status on circadian rhythm and 
metabolic gene expression in C2C12 myoblasts and myotubes and (II) examine the oxidative 
capacity of mitochondrial in synchronized C2C12 myoblasts. The hypothesis of this study was 
that with disrupted iron homeostasis, circadian rhythm and circadian controlled metabolic gene 
expression will be altered.  
In this study, the effect of iron chelation and iron treatment in response to circadian 
rhythm and metabolism was analyzed by utilizing synchronized C2C12 myoblast model. C2C12 
myoblasts have the potential to differentiate into myotubes and form contractile muscle fibers, 
making the model physiological relevance. Low serum (2% horse serum DMEM) media is used 
for differentiating proliferating myoblasts to myotubes [135]. Synchronization of C2C12 cells is 
important in circadian rhythm study and serum shock technique has been practice over the past 
decades and common in circadian study.
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To examine the extent to which iron chelation and iron loading alters changes in iron 
labile pool, IRP1 and IRP2 spontaneous and total RNA binding activity is the optimal 
measurement for iron deficiency and iron overloading in cells. The spontaneous binding activity 
for IRP1 and IRP2 in DFO treated cells was increased by 2.1-fold while FAC and hemin treated 
cells showed a decreased of 0.25- and 0.2-fold, respectively (data not shown; n = 1). Total RNA 
binding activity of IRP1 was also measured to ensure that the spontaneous RNA binding activity 
of IRP1 is due to a shift in [4Fe-4S] containing cytosolic-aconitase losing [4Fe-4S] cluster, 
leaving IRP1 in its active binding form. 
Alteration of circadian and metabolic genes over 24 hour period 
With validation of the C2C12 low iron and high iron model by IRPs RNA binding 
activity. We examine the extent to which iron status alters circadian rhythmicity in C2C12 
myoblast cells by collecting cells sample every 6 h for a period of 24 h after treatment. We 
hypothesized that with iron chelation by DFO, Tfrc gene expression would be up-regulated due to 
Tfrc mRNA stabilization by IRPs. Moreover, with decrease in labile iron pool, heme biosynthesis 
is hypothesized to be down regulated as well as Bmal1 gene expression which is regulated by 
heme-mediated REV-ERBα. Tfrc is not a circadian gene and does not regulate in a circadian 
manner, however, its transcription is affected by iron availability in the cells. At ZT18, Tfrc gene 
expression peaked by 2.5-fold (p = 0.016). From ZT18 to ZT 24, Bmal1 gene expression peaked 
from 2.1-fold to 5.1-fold (p = 0.040). Rev-erbα gene expression started to show significant 
increase at ZT18 (2.0-fold; p = 0.013) and continue to be up-regulated at ZT24 (2.7-fold; p = 
0.033). The circadian genes Alas1, Bmal1 and Rev-erbα showed circadian rhythmicity, ensuring 
that synchronization occurs within the cells. In DFO treated cells, Alas1 gene expression peaked 
2.6-fold (p =0.007) at ZT12 indication an increased in the conversion of acetyl-CoA and glycine 
to ALA (aminolevuleneic acid). The up-regulation of Tfrc further validated low iron C2C12 
model. These results demonstrate that low iron status in the C2C12 cells potentially lead to up-
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regulation of Alas1 which drives heme biosynthesis. Despite an increase in Alas1 gene 
expression, the final product of heme production requires incorporation of ferrous iron by the 
action of ferrochelatase which is down-regulated due to low iron availability and possibly less 
production of ferrochelatase. With less heme production, Bmal1 gene expression is up-regulated 
due to the de-repression of REV-ERBα and competitive binding of RORα on Bmal1 promoter. 
Increased gene expression of Rev-erbα suggested that there is an increased production of BMAL1 
resulted in increased in CLOCK:BMAL1 heterodimers for regulation of Rev-erbα. This 
confirmed our hypothesis that changes in iron status (low iron) lead to alteration in circadian gene 
expression in C2C12 myoblasts. 
FAC and hemin were used as iron loading sources.  In FAC treated cells, up-regulation of 
Alas1 was observed and it is hypothesized to be regulated by PGC-1α due to production of ROS 
from free iron [3]. Despite an increased in Alas1 regulation, the availability of iron source for 
heme biosynthesis increased resulting in more heme availability. Heme binds to REV-ERBα 
which repressed gene expression of Bmal1. Less CLOCK:BMAL1 heterodimers are formed and 
thus causing a delay in the downstream Rev-erbα gene expression by 6 h. Tfrc in FAC treated 
cells were not significantly repressed, therefore, the changes observed in circadian and metabolic 
gene expression may occur with minimal increase in iron. 
In hemin treated cells, down regulation of Alas1 was expected as heme is a direct 
inhibitor of Alas1 gene expression. Bmal1 mRNA level was lowered from ZT0 to ZT24 but 
values were not significant. The slightly lowered Bmal1 gene expression may correlates with the 
slight change in trough and peaked of Rev-erbα gene expression despite no change in oscillation 
was observed. In hemin treated cells, Tfrc gene expression was significantly lowered at ZT6 and 
ZT24, making it a high iron C2C12 myoblast model. 
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In conclusion, changes in iron status in C2C12 proliferating myoblasts exhibit variation 
in diurnal expression of circadian (Alas1, Bmal1 and Rev-erbα) and iron metabolic gene 
expression (Tfrc). Alteration in heme biosynthesis rate-limiting enzyme gene expression Alas1 
may potentially play a role in regulation of Bmal1 by heme-mediated REV-ERBα. 
Alteration of circadian and metabolic genes at ZT18 
 In DFO treated cells, Rorα and Rev-erbα were significantly up-regulated which may 
indicate increased in regulation by CLOCK:BMAL1 heterodimer. In agreement with previous 
literatures, Pdk4 gene expression increased may be due to increase in Pgc-1α, Hif1α, ERRα 
and/or PPAR gene expression due to DFO treatment [48], [109], [147], [148]. Interestingly, ID 
rat’s skeletal muscle displayed a decreased in Pdk4 gene expression [53]. The explanation for 
these different could be due to the global regulation of rat’s skeletal muscle, however, cell culture 
regulation of Pdk4 maybe specific to skeletal muscle. 
 In FAC treated cells, Rev-erbβ was down-regulated as well as other metabolic gene 
expression such as MyoD, Pdk4, and Srebp-1c. Despite an increased in Pgc-1α gene expression, 
Pdk4 gene expression is down regulated indicating other modulator (i.e. HIF1α) of Pdk4 gene 
expression is involved [56]. Alas1 gene expression is regulated by its coactivator Pgc-1α, leading 
to up-regulation in heme biosynthesis. Repression of MyoD and Srebp-1c is expected with 
increased in heme-mediated REV-ERBs activity. REV-ERBs repressed Bmal1 gene expression 
resulting in decreased Rev-erbβ gene expression. 
 In hemin treated cells, Hmox-1 gene expression was up-regulated resulting in breakdown 
of heme into ferrous iron, biliverdin and CO. The increase in availability of free iron induces 
ROS and eventually PGC-1α production. Intriguingly, Pgc-1β gene expression decreased. Similar 
to FAC treated cells, MyoD and Pdk4 are down-regulated in hemin treated cells which may 
potentially be regulated by increase in Pgc-1a gene expression. In this study, changes in iron 
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status in C2C12 proliferating myoblasts exhibit variation in circadian, heme biosynthesis and iron 
metabolic gene expression. 
Mitochondria oxidative capacity 
 Significant increase in mitochondria oxidative capacity was observed in FAC and hemin 
treated cells. However, no significant change was observed despite a downward trend in oxidative 
capacity. The mitochondria stress test showed that iron is important in regulating mitochondria 
function and necessary for proliferating skeletal muscle cells. This test suggest that iron is 
required for mitochondria function and overloading iron may potentially increase heme 
biosynthesis and iron sulfur cluster for making of ISCU, hemoprotein, and mitochondria 
complexes. 
Interesting findings 
 Pgc-1α is up-regulated while Pgc-1β is down-regulated in all treatment. This alteration in 
Pgc-1 family maybe due to ROS production due to disruption in iron homeostasis [3]. Rorα was 
significantly up-regulated in DFO treated cells but no change was observed in FAC or hemin 
treatment. Pdk4 was significantly up-regulated in DFO but down-regulated in FAC and Hemin. 
This may suggest an important role iron in the regulation of Rora and Pdk4, however, future 
study is needed to understand the mechanism. 
Study Limitation 
There are several limitations of the study on iron status and circadian rhythm. The 
commonly used model of circadian rhythmicity is C2C12 myotubes due to its ability to contract 
and produce proteins involves in differentiation muscle. However, study of iron status is very 
sensitive to amount of iron (transferrin) present in the serum in the media. The low serum 
condition is similar to low transferrin condition in media, therefore, the media affects iron 
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chelation and iron loading treatment in our study. Differentiation required cells to be grown in 
low serum media (2% horse serum) and this low serum mimics the effect of iron chelation by 
DFO by having induction in Tfrc gene expression (data not shown).  Therefore, the better model 
to study iron status is in C2C12 myoblast where cells are grown in 10% FBS in DMEM for the 
entire experiment. Moreover, the effect of iron loading was greatly potentiated since the media is 
low in iron (transferrin). Furthermore, most common form of iron in myotubes is heme-
containing protein and DFO is unable to chelate iron from hemoprotein such as myoglobin. 
Therefore, differentiated C2C12 cells were not affected by DFO treatment, even at high 
concentration (1000 μM) which may be toxic to many proliferating cells. 
Tfrc gene expression is commonly used in measuring the iron status, however, it is not as 
sensitive as measuring the spontaneous binding activity of IRP1 and IRP2.This study is lacking 
sufficient data to support the validity of iron deficient or iron overloading model. Despite that, 
Tfrc gene expression is a good indicator and downstream target genes of IRPs and IRE. 
The present study has shown that proliferating C2C12 myoblast display diurnal variation 
in response to iron chelation and iron treatment at the level of gene expression. In contrast, we 
have not investigate whether the observed gene expression are associated with concomitant 
changes in protein expression. Moreover, the present study has not determined the relationship 
between changes in diurnal variation in circadian gene expression and the metabolic changes as 
well as mitochondrial respiratory activity in C2C12 cells. Additionally, we have not defined the 
mechanism(s) responsible for skeletal muscle variation in metabolic gene expression (MyoD and 
Pdk4) in this cell model.   
In conclusion, the results presented demonstrate that iron status affects circadian rhythm 
and metabolic gene expression in C2C12 myoblasts. To further assess the direct binding of REV-
ERBα to Bmal1 gene promoter in these cells, we plan to perform chromatin immunoprecipitation 
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(ChIP) assay on C2C12 purified DNA products that has been crosslinked which stabilizes 
protein-DNA complexes in the cell and assess in interaction with qPCR. Moreover, we plan to 
perform western blots on cytosolic protein extracts to analyze the changes in protein expression 
of PGC-1α and HIF1α to better explain the mechanism involved in Pdk4 overexpression in DFO 
treated cells. Since heme is the direct regulator of REV-ERBs, we also plan to measure heme 
concentration in these cells via heme colorimetric assays. This may validate if heme biosynthesis 
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